Nissan to Potentially Build a New Honda Pickup in U.S
Images shown in this article depict the current Honda Ridgeline and do not represent the potential new pickup under discussion.
This market gap appears to be motivating Honda to consider a major strategic shift. The company is reportedly in talks with Nissan to produce a new Honda pickup in the U.S., with manufacturing potentially taking place at Nissan's facility in Canton, Mississippi. The move would allow Honda to offer a more traditional, body-on-frame truck — likely based on the Nissan Frontier — without having to design and build a new model from scratch.
The Canton plant currently builds the Frontier and the Altima. With the Altima nearing the end of its production run and delays affecting Nissan's electric vehicle plans, the facility has available capacity. That makes it a prime candidate for a manufacturing collaboration that could benefit both brands.
For Honda, this partnership would open the door to a new kind of Honda pickup — one that's better suited to the expectations of conventional truck buyers. It also allows Honda to increase its domestic production footprint, which would help minimize tariff exposure and strengthen supply chain resilience.
For Nissan, the deal would improve efficiency at a plant that's currently operating well below full capacity. Adding volume through a new production arrangement could make a meaningful impact on the plant's profitability and long-term sustainability.
While no official confirmation has been made, a rebadged or slightly modified version of the Frontier carrying Honda's name seems to be the most likely outcome. Whether this new Honda pickup would replace the Ridgeline or be sold alongside it remains to be seen.
In either case, the collaboration signals a strategic evolution. Honda gains access to a proven truck platform, while Nissan capitalizes on underused resources. Together, they could deliver a product that fills a critical gap in Honda's U.S. lineup — and finally gives the brand a foothold in the fiercely competitive world of traditional pickups.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Al Arabiya
26 minutes ago
- Al Arabiya
Sarepta shares slide again as drugmaker bows to FDA pressure to pause gene therapy
Shares of drugmaker Sarepta Therapeutics continued to fall Tuesday after the company said it would comply with a Food and Drug Administration request to pause shipments of its gene therapy following several patient deaths. The decision announced late Monday comes just days after the company rebuffed FDA regulators in an extremely unusual decision that alarmed investors and analysts. Sarepta CEO Doug Ingram said the company seeks a productive and positive relationship with FDA and that maintaining that productive working relationship required this temporary suspension. The Cambridge Massachusetts-based company said it would temporarily pause all shipments of its gene therapy Elevidys for muscular dystrophy at the close of business Tuesday. It's the latest in a series of highly irregular moves that have rocked company shares for weeks and forced it to lay off hundreds of staffers. Elevidys is the first gene therapy approved in the US for Duchennes muscular dystrophy–the fatal muscle-wasting disease that affects boys and young men resulting in early death. The one-time treatment was initially approved for boys age 4 and younger who could still walk. Last year FDA expanded approval to older patients who are no longer able to walk. The therapy was already under FDA scrutiny after two teenage boys died earlier this year from acute liver injury–a known side effect of the treatment. Then the company last week disclosed a third death with a different therapy: a 51-year-old patient who was enrolled in a company trial for another form of muscular dystrophy. FDA responded by asking the company to immediately halt all shipments of Elevidys. Wall Street analysts said the company made the right move. 'Defying the FDA would have irreparably damaged the company's relationship with FDA under the current leadership and administration,' TD Cowen analyst Ritu Baral told investors in a note Tuesday. Baral estimated the pause in distribution would last three to six months. The FDA has the authority to pull drugs from the market, but the process can take months or even years. Instead, the agency usually makes an informal request and companies almost always comply. Even in the rare cases when drugmakers haven't cooperated, the FDA has prevailed after public hearings and appeals.
Al Arabiya
26 minutes ago
- Al Arabiya
Takeaways from AP's report about cuts to government grants for nonprofits
President Donald Trump's policies are poised to upend decades of partnerships the federal government has built with nonprofits to help people in their communities. Since the 1960s, presidential administrations from both parties have used taxpayer dollars to fund nonprofits to take on social problems and deliver services. A vast and interconnected set of federal grants fund public safety programs, early childhood education, food assistance, and refugee resettlement services in every state. In January, the Trump administration sought to freeze federal grants and loans. Nonprofit groups immediately challenged the move and won a court-ordered pause. But in the six months since, the administration has cut, frozen, or discontinued many federal grant programs across agencies. An analysis by the Urban Institute provides a sense of the scale and reach of government support for nonprofits. Published in February, the data comes from the tax forms nonprofits file where they report any government grants they receive. In response to questions about the cuts to grant funding, White House spokesperson Kush Desai said, 'Instead of government largesse that's often riddled with corruption, waste, fraud, and abuse, the Trump administration is focused on unleashing America's economic resurgence to fuel Americans' individual generosity.' How much support does the government give to nonprofits? The Urban Institute found $267 billion was granted to nonprofits from all levels of government – federal, state, and local – in 2021, the most recent year a comprehensive set of nonprofit tax forms are available. That figure underestimates the total funding nonprofits receive from the government. It includes grants but not contracts for services nor reimbursements from programs like Medicare. It also excludes the smallest nonprofits which file a different abbreviated tax form. The data includes all tax-exempt organizations that file a full tax return, from local food pantries to universities and nonprofit hospitals. But government funding does not just go to the largest organizations. A majority of nonprofits in the dataset, across every sector from the arts to the environment to human services, report receiving government grants. In most places, the typical nonprofit would run a deficit without government funding. The Urban Institute cautions that just because a nonprofit would run a budget deficit without government funding, it does not necessarily mean the nonprofit will close. Even in wealthy areas, nonprofits would struggle without government support. In only two Congressional districts – one that includes parts of Orange County, California, and one in the suburbs west of Atlanta – would typical nonprofits not be in the red if they lost all of their public grant funding, the analysis found. However, funders in Orange County warn that nonprofits are not as optimistic about their resiliency. Taryn Palumbo, executive director of Orange County Grantmakers, said local nonprofits are seeing their budgets getting slashed by 50 percent or 40 percent. Last year, a large local foundation, Samueli Foundation, commissioned a study of nonprofit needs because they were significantly increasing their grantmaking from $18.8 million in 2022 to an estimated $125 million in 2025. They found local nonprofits reported problems maintaining staff, a deep lack of investment in their operations, and a dearth of flexible reserve funds. The foundation responded by opening applications for unrestricted grants and to support investments in buildings or land. Against this $10 million in potential awards, they received 1,242 applications for more than $250 million, said Lindsey Spindle, the foundation's president. 'It tells a really stark picture of how unbelievably deep and broad the need is,' Spindle said. 'There is not a single part of the nonprofit sector that has not responded to these funds. Every topic you can think of: poverty, animal welfare, arts and culture, civil rights, domestic abuse.' Private donations can't replace government support. The nonprofit Friendship Shelter helps house and support 330 people in Laguna Beach, California, which falls within Orange County. Dawn Price, its executive director, said the organization has an annual budget of about $15 million, $11.5 million of which comes from government sources. Price said the government funding is braided in complex ways to support different programs and fill in gaps. Private donors already subsidize their government grants, which she said pay for 69 percent of the actual program costs. 'We are providing this service to our government at a loss, at a business loss, and then making up that loss with these Medicaid dollars and also the private fundraising,' she said. Even in a wealthy place like Orange County, Price said she does not believe private donors are prepared to give five, six, or eight times as much as they do currently if new cuts to government grants occur or programs are not renewed.
Al Arabiya
3 hours ago
- Al Arabiya
Coca-Cola reports weakening global sales volumes in second quarter
Coca-Cola reported better-than-expected earnings in the second quarter as higher prices offset weaker sales volumes. Case volumes fell 1 percent globally and 1 percent in North America, but Coke said Tuesday that pricing rose 6 percent for the April-June period. Revenue for the Atlanta company rose 1 percent to 12.5 billion. Adjusted for one-time items, quarterly revenue was 12.6 billion. That was in line with Wall Street's forecast, according to analysts polled by FactSet. Net income jumped 58 percent to 3.8 billion. Its adjusted net income was 87 cents, which was higher than the 83 cents Wall Street forecast. Coke said Tuesday it now expects full-year adjusted earnings to grow 8 percent. At the start of the year, Coke had expected earnings to grow 8 percent to 10 percent, but in April it lowered that range to 7 percent to 9 percent. Coke earned 2.88 per share in 2024. Shares of Coca-Cola Co. were down slightly early Tuesday, as were all major US markets.
